Pharmacology of platinum compounds: Differences between the three molecules and factors of interpatient variability;Pharmacologie des dérivés du platine: Différences entre les trois composés et les facteurs de variabilité entre patients

Bulletin du Cancer

Volumn 98, Issue 11, 2011, Pages 1253-1261

  Chatelut, Étienne ^a  

^a UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

Carboplatin; Cisplatin; Oxaliplatin; Pharmacokinetics

Indexed keywords

CARBOPLATIN; CISPLATIN; OXALIPLATIN;

ANTINEOPLASTIC ACTIVITY; CANCER RESISTANCE; DNA ADDUCT; HUMAN; REVIEW;

EID: 82455191632     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2011.1464     Document Type: Review

References (21)

1. Fuertes MA, Alonso C, Perez JM. Biochemical modulation of cisplatin mechanisms of action: enhancement of antitumor activity and circumvention of drug resistance. Chem Rev 2003; 103 : 645-62.
2. Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007; 33 : 9-23. (Pubitemid 46137553)
3. Song IS, Savaraj N, Siddik ZH, et al. Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells. Mol Cancer Ther 2004; 3 : 1543-9. (Pubitemid 40136709)
4. Rudin CM, Yang Z, Schumaker LM, et al. Inhibition of glutathione synthesis reverses Bcl-2-mediated cisplatin resistance. Cancer Res 2003; 63 : 312-8. (Pubitemid 36152486)
5. Martin LP, Hamilton TC, Schilder RJ. Platinum resistance: the role of DNA repair pathways. Clin Cancer Res 2008; 14 : 1291-5. (Pubitemid 351413906)
6. Fink D, Nebel S, Aebi S, et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Res 1996; 56 : 4881-6. (Pubitemid 26374423)
7. Daley-Yates PT, McBrien DC. The mechanism of renal clearance of cisplatin (cis-dichlorodiammine platinum II) and its modification by furosemide and probenecid. Biochem Pharmacol 1982; 31 : 2243-6. (Pubitemid 12085287)
8. Burger H, Zoumaro-Djayoon A, Boersma AW, et al. Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2). Br J Pharmacol 2010; 159 : 898-908.
9. Yokoo S, Yonezawa A, Masuda S, Fukatsu A, Katsura T, Inui K. Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity. Biochem Pharmacol 2007; 74 : 477-87. (Pubitemid 46963232)
10. Hartmann JT, Lipp HP. Toxicity of platinum compounds. Expert Opin Pharmacother 2003; 4 : 889-901. (Pubitemid 36722480)
11. Chevreau C, Thomas F, Couteau C, Dalenc F, Mourey L, Chatelut E. Ototoxicity of high-dose carboplatin. J Clin Oncol 2005; 23 : 3649-50.
12. Loos WJ, de Jongh FE, Sparreboom A, et al. Evaluation of an alternate dosing strategy for cisplatin in patients with extreme body surface area values. J Clin Oncol 2006; 24 : 1499-506. (Pubitemid 46638770)
13. Egorin MJ, Jodrell DI. Utility of individualized carboplatin dosing alone and in combination regimens. Semin Oncol 1992; 19 : 132-8.
14. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989; 7 : 1748-56. (Pubitemid 19272848)
15. Chatelut E, Canal P, Brunner V, et al. Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst 1995; 87 : 573-80.
16. Schmitt A, Gladieff L, Lansiaux A, et al. A universal formula based on cystatin C to perform individual dosing of carboplatin in normal weight, underweight, and obese patients. Clin Cancer Res 2009; 15 : 3633-9.
17. Lord RV, Brabender J, Gandara D, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002; 8 : 2286-91. (Pubitemid 34753602)
18. Cobo M, Isla D, Massuti B, et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 2007; 25 : 2747-54. (Pubitemid 47123183)
19. Sculier JP, Lafitte JJ, Efremidis A, et al. A phase III randomised study of concomitant induction radiochemotherapy testing two modalities of radiosensitisation by cisplatin (standard versus daily) for limited small-cell lung cancer. Ann Oncol 2008; 19 : 1691-7.
20. Motzer RJ, Mazumdar M, Sheinfeld J, et al. Sequential doseintensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients. J Clin Oncol 2000; 18 : 1173-80. (Pubitemid 30159833)
21. Elias D, Bedard V, Bouzid T, et al. Malignant peritoneal mesothelioma: treatment with maximal cytoreductive surgery plus intraperitoneal chemotherapy. Gastroenterol Clin Biol 2007; 31 : 784-8. (Pubitemid 350261618)